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1. Health Economics Analysis Plan 
1.1 Purpose of plan 
The purpose of this health economics analysis plan is to describe the analysis and reporting 
procedure intended for the economic analyses to be undertaken in the PANDA RCT.  The analysis 
plan is designed to ensure that there is no conflict with the protocol and associated statistical 
analysis plan (SAP), and it should be read in conjunction with them. 
 
The plan also describes the circumstances under which amendments to planned analysis are 
permitted and the documentation of such changes; any deviations from this plan will be justified in 
the final report.  The analysis plan is designed as a working document that will evolve throughout 
data collection, data cleaning and preliminary descriptive analysis. The analysis plan will be finalised 
before any unblinded comparison between trial arms, with the exception of the section on post-hoc 
analyses.   
1.2 Economic analysis background 
Aim 
A full description of the study context, setting, patients and interventions is provided in the study 
protocol. Briefly, the PANDA RCT aims to inform primary care prescribing practice by investigating 
the severity and duration of depressive symptoms that are associated with a clinically significant 
response to sertraline compared to placebo, in people presenting to primary care with depression.  
Participants who consented to participate in the trial will be randomised to receive either sertraline 
or matching placebo, starting at 50 mg daily for 1 week, increasing to 100 mg daily for up to 11 
weeks and then for a 2-week tapering period. Participants, their GPs and the research team will be 
blind to treatment allocation. 
 
The aim of the economic analysis was to estimate the cost-effectiveness of sertraline in comparison 
to placebo at the end of 12 weeks follow-up in relation to the baseline severity and duration of 
depressive symptoms. Secondary analysis will estimate the cost-effectiveness of sertraline in 
comparison to placebo.  
Perspective 
The primary economic analysis will be from the NHS and personal social services (PSS) perspective. A 
secondary analysis will be undertaken from the perspective of individual patients, accounting for 
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costs such as expenditure on private health care. We will also consider the cost to society of work 
absences.  
Time horizon 
The time horizon for the economic analysis will be up to 12 weeks to reflect the duration of follow-
up in the trial. As the follow-up period does not extend beyond one year, discounting of costs and 
benefits will not be applied. 
1.3 Economic measurements 
Identification of outcomes 
The primary economic outcome measure will be Quality Adjusted Life Years (QALYs) derived from 
utility scores, obtained using the EQ-5D-5L quality of life instrument[1]. 
Measurement of outcomes  
Measurements will be recorded prior to randomisation (baseline), 2 weeks, 6 weeks and 12 weeks 
post-randomisation.   Baseline and research follow-up assessments will take place at the 
participant’s home, general practice, or at university premises.    
Valuation of outcomes 
Utility scores will be derived from responses to the EQ-5D-5L using valuations obtained from an 
English population [2]. These will be used to form Quality Adjusted Life Years (QALYs) over the 12-
week period, adjusting for any imbalances in baseline EQ-5D-5L scores [3].  
Identification of relevant resource use 
The process of analyzing resource use in the two arms of the trial involves: 
– Identifying the category of resource items used; 
– Measuring the quantum of resources used in each category;  
– Valuing these quanta of resource use using unit costs. 
 
The analysis will identify which resources are used, calculate a unit cost, and then value overall 
resource use in each arm of the trial by multiplying unit costs for every item by the associated 
number of units used.  
 
For the NHS and PSS perspective, data will be collected on use of health services in primary and 
secondary care including primary care appointments, prescribed medication, hospital admission and 
outpatient attendance, and community-based care.  
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For the analysis including the patient perspective, we will additionally collect data on travel costs 
and expenditure on over-the-counter medication, and private therapies and treatments.   The value 
of productivity losses will be estimated using data on time off work by patients.  
Measurement of resource use 
Health and social care resource use 
Primary care appointments with GPs, practice nurses or healthcare assistants GP will be captured 
through electronic downloads of GP records; manual data capture may be used as a back-up if GP 
records do not support automatic downloads.  
 
NHS secondary care, community care, care from social services and patient personal resource use 
during trial follow-up will be captured using patient-reported questionnaires at 2, 6 and 12 weeks. 
Examples of the resource use questionnaire are provided in Appendix 1. Our base case analysis will 
include costs associated with all primary care, community based care and secondary care.  
 
Sensitivity analysis will examine the impact of excluding secondary care and prescriptions extracted 
from medical records that are judged to be not directly related to the treatment of depression. This 
will involve a blinded assessment by clinically-qualified co-investigators of all medications (excluding 
drug classes used for depression) and of secondary care episodes. A simple tripartite classification 
will be used of “probably directly related”, “probably not directly related”, and “unsure”.  We will 
also conduct a further sensitivity analysis removing all secondary care from cost analyses. This will 
assess whether recall bias, misclassification, or infrequent but expensive events differed between 
arms. 
Productivity 
Time off work by patients will be captured in the patient-reported questionnaires (see appendix).  
Personal expenditure on healthcare 
Expenditure on over-the-counter medication, and private use of treatments and therapies will be 
captured in the patient-reported questionnaires at 2, 6 and 12 weeks.  
Valuation of resource use  
The cost of each resource item will be calculated by multiplying the number of resource units used 
by the unit cost. The total cost for each individual patient will then be estimated as the sum of the 
cost of resource-use items consumed. The level of detail employed in each step of this analysis will 
depend on the likelihood that there will be an economically important incremental difference in 
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resource use between arms. Drummond et al [1] note that judgment must be formed on how 
precise cost estimates need to be in a particular study, stating that ‘It is not worth investing a great 
deal of time and effort considering costs that, because they are small, are unlikely to make a 
difference to the study result…It is still worthwhile identifying such cost categories in any event, 
although the estimation of them might not be pursued in any great detail’ 
 
The costs of medications will be estimated from the British National Formulary. We will assign a zero 
value to the cost of the placebo therapy used in the control arm. Community and primary care costs 
will be based on national estimates [4]. Codes for Healthcare Resource Groups (groups of events 
that have been judged to consume similar levels of resources) will be assigned to secondary care 
contacts and will be costed based on the most recently published national reference costs where 
available (e.g. DOH [5]). Productivity costs will be estimated based on national average weekly 
earnings stratified by sex (e.g. ONS [6]). Resource use will be combined with unit costs to estimate 
the incremental cost of the PANDA intervention.  
 
All costs will be reported for the most recent cost year available in pounds sterling, adjusted for 
inflation if necessary.   
1.4 Economic analyses 
A cost-effectiveness analysis will be conducted using intention-to-treat principles, comparing the 
two groups as randomised and including all patients in the analysis. This analysis will estimate how 
net monetary benefit (see below) varies with baseline severity and with symptom duration. A 
separate descriptive, non-inferential cost-consequence analysis [7] will compare NHS, PSS and 
personal costs to response against the primary trial outcome of depressive symptoms  measured by 
the PHQ-9 at 6 weeks post-randomization.   
Data cleaning and missing costs and outcomes 
We will undertake exploratory analysis to ensure ranges and distributions of variables used in the 
economic analysis are appropriate. We will also present by arm descriptive statistics of data, such as 
means, medians, and frequencies.  
 
We will liaise with trial statisticians and project manager in identifying issues with data such as mis-
codings. Data cleaning and imputation will be undertaken prior to unblinding by the economic 
researcher. Data cleaning will include correction of obvious 'free text' response errors (e.g. misspelt 
drug names), group coding of similar resource items (e.g. 'orthopaedics' and 'trauma & 
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orthopaedics' clinics) to enable unit costing, and simple imputation of data missing minor details 
(e.g. missing drug dose) based on reasonable assumptions, provided that this simple imputation can 
be undertaken conservatively.  Any remaining areas of uncertainty will be discussed between two 
health economists and, where necessary, referred for adjudication by a clinical expert.  
 
The primary analysis will include all participants using multiple imputation to predict missing costs 
and outcomes [8, 9].  If possible the same imputation models will be used for the primary 
effectiveness analysis and the economic evaluation.  The approach taken to missing data and any 
imputation will be clearly justified in terms of best practice[9] and the characteristics of the data. 
The exact specification of an imputation model will depend on the level of missingness of each 
variable but it will be stratified by arm, and will include available cost measurements, trial arm as a 
covariate, age, sex, and available EQ-5D-5L scores. There will be a clear discussion of the equations 
used in any multiple imputation, in line with best practice recommendations [2]. The software 
package and software version used for multiple imputation will be reported.  We will follow the 
CONSORT recommendation in stating the number of patients included in each analysis.  
Analysis of outcomes 
We will report the incremental mean difference in QALYs between the two arms of the trial and 95% 
confidence intervals using linear regression.  
Analysis of costs 
Overall mean costs and measures of their variance, stratified by NHS & PSS, patient and productivity 
costs for both arms of the trial will be calculated.  We will estimate the incremental mean difference 
in total costs between the two arms of the trial and 95% confidence intervals using linear regression.  
Analysis of cost-effectiveness  
Cost and QALY data will be combined to calculate an incremental cost-effectiveness ratio (ICER) and 
net monetary benefit (NMB) statistic [10] from the NHS and PSS perspective. 
 
NMBi = λ Ei–Ci       
 
For each individual i, the NMB statistic is given as the cost-effectiveness threshold, λ, multiplied by 
the patient outcome Ei  (i.e. QALYs), from which the total cost Ci is subtracted.  In the primary 
analysis we will estimate whether the PANDA intervention is cost-effective at a NICE threshold value 
of £30,000 per QALY. The purpose of the primary analysis will be to determine how estimates of 
NMB vary with baseline severity and with symptom duration. We will identify the threshold level of 
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severity and duration, if any, at which sertraline becomes cost-effective in comparison to placebo, as 
measured by NMB. We will do this by calculating NMB regressions [11, 12] using interactions 
between the treatment indicator and baseline severity, and in a separate model between the 
treatment indicator and symptom duration. Uncertainty in the point estimate of cost per QALY will 
be quantified using regression methods to calculate confidence intervals around the NMB. We will 
calculate cost-effectiveness acceptability curves (CEACs) to indicate how the cost-effectiveness of 
sertraline changes with respect to the cost-effectiveness threshold, while accounting for interactions 
between severity and depression.  
 
We will conduct a subgroup analysis estimating NMB according to higher and lower baseline 
severity, and according to longer and shorter symptom duration. We will also undertake a secondary 
analysis estimating the cost-effectiveness of sertraline to placebo, irrespective of baseline severity 
and symptom duration. All regression models will adjust for study centre as random effects or other 
similar methods to reflect site-specific variation.    
1.5 Further economic analyses 
Further sensitivity analyses 
The following sensitivity analyses, not already described above, will be conducted  
 Complete case analysis 
 An imbalance between arms in the number of deaths is not anticipated. However, such an 
imbalance, were it to be observed in the trial, could have a material impact on the between-
arm comparison. If such an imbalance is observed, a sensitivity analysis excluding people 
who have died will also be conducted. 
Subgroup analysis 
As noted, we will undertake a subgroup analysis of net benefit by baseline severity and by net 
benefit.  Any other subgroup analyses developed after unblinding will be described as post hoc 
analysis.  
1.6 Updating the economic analysis plan 
Changes to existing analyses 
Dated changes to the analysis plan will be documented (see page 2) in this section. We will update 
the version number reported on the front page and in the footer of the document.   Circumstances 
under which changes will be permitted are as follows. 
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 Development of statistical methods that are deemed more appropriate for this 
analysis. 
 Clarification of currently debated issues. 
 Preliminary data cleaning or analysis (conducted prior to unblinding) suggesting that 
planned analyses may require amendment.  
Post hoc analyses 
Any suitable analyses that are identified after unblinding or during the refereeing process will be 
listed in this section, described as “changes to existing analyses”, dated and the source of proposed 
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Appendix 1.  Examples of resource use data collected 
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